Experimental Study On Interferon α2b Combined With Marine And Thymosin α1 In The Treatment Of Chronic Hepatitis B

Objective To evaluate the experimental efficacy of interferon α2bcomibined with marine and thymosin α1. Methods 98 chronic hepatitsB patients were enrolled and randomized into the therapy group and thecontrol group.49 cases in the therapy group received interferonα2b,marine and thymosin α1 for 13 weeks,then interferon α2b andthymosin α1 for 13weeks,at last interferonα2b simultaneously for 26weeks;49 cases in the control group received interferon α2b alone for 52weeks.During the treatment blood routine examination,ALT,HBeAg,Anti-HBe,HBVDNA and HA were termly checked and measured.Results ALL 98 patients completed the study. The rates for ALT and HAto recover to normal and the rates for HBeAg and HBVDNA to change tobe negative in combination group were superior to those in interferonα2bgroup.(81.6%vs53.1% , P < 0.005 ; 44.9%vs22.4% , P < 0.025 ;42.9%vs20.4%,P<0.025;79.6%vs51.0%,P<0.005 ).Conclusions Theefficacy of combination therapy appeared to be better than interferon α2b group.